Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The closing price of EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) was $11.83 for the day, up 1.98% from the previous closing price of $11.6. In other words, the price has increased by $1.98 from its previous closing price. On the day, 0.68 million shares were traded. EYPT stock price reached its highest trading level at $12.1423 during the session, while it also had its lowest trading level at $11.4.
Ratios:
Our analysis of EYPT’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 7.91 and its Current Ratio is at 8.00. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, RBC Capital Mkts on June 17, 2025, initiated with a Outperform rating and assigned the stock a target price of $28.
On January 07, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $33.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 19 ’25 when Zaderej Karen L. bought 5,000 shares for $5.99 per share. The transaction valued at 29,950 led to the insider holds 36,500 shares of the business.
Zaderej Karen L. bought 5,000 shares of EYPT for $29,050 on May 16 ’25. The Director now owns 31,500 shares after completing the transaction at $5.81 per share. On May 15 ’25, another insider, Zaderej Karen L., who serves as the Director of the company, bought 5,000 shares for $5.47 each. As a result, the insider paid 27,350 and bolstered with 26,500 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EYPT now has a Market Capitalization of 815411136 and an Enterprise Value of 583393408. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.71 while its Price-to-Book (P/B) ratio in mrq is 3.31. Its current Enterprise Value per Revenue stands at 11.241 whereas that against EBITDA is -3.117.
Stock Price History:
The Beta on a monthly basis for EYPT is 1.94, which has changed by 0.272043 over the last 52 weeks, in comparison to a change of 0.1513431 over the same period for the S&P500. Over the past 52 weeks, EYPT has reached a high of $13.98, while it has fallen to a 52-week low of $3.91. The 50-Day Moving Average of the stock is 16.68%, while the 200-Day Moving Average is calculated to be 47.74%.
Shares Statistics:
EYPT traded an average of 793.17K shares per day over the past three months and 759800 shares per day over the past ten days. A total of 68.89M shares are outstanding, with a floating share count of 60.27M. Insiders hold about 12.56% of the company’s shares, while institutions hold 89.93% stake in the company. Shares short for EYPT as of 1753920000 were 6910406 with a Short Ratio of 8.71, compared to 1751241600 on 6934144. Therefore, it implies a Short% of Shares Outstanding of 6910406 and a Short% of Float of 12.020000999999999.
Earnings Estimates
Investors are keenly observing as 10.0 analysts analyze and rate the current performance of EyePoint Pharmaceuticals Inc (EYPT) in the stock market.The consensus estimate for the next quarter is -$0.75, with high estimates of -$0.58 and low estimates of -$0.95.
Analysts are recommending an EPS of between -$2.75 and -$3.4 for the fiscal current year, implying an average EPS of -$3.03. EPS for the following year is -$2.93, with 10.0 analysts recommending between -$1.74 and -$4.23.
Revenue Estimates
A total of 13 analysts have provided revenue estimates for EYPT’s current fiscal year. The highest revenue estimate was $53.2M, while the lowest revenue estimate was $29.79M, resulting in an average revenue estimate of $36.08M. In the same quarter a year ago, actual revenue was $43.27M
